Alnylam Pharmaceuticals (ALNY) Income Statement: Revenue & Earnings

Alnylam Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in billions USD

Scale:

Scroll to see more

Alnylam Pharmaceuticals, Inc. income statement - Annual data in billions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	3.71	2.25	1.83	1.04	0.84	0.49	0.22	0.07	0.09
Cost of Revenue	0.68	0.32	0.31	0.17	0.14	0.08	0.03	0.00	0.01
Gross Profit	3.04	1.92	1.52	0.87	0.70	0.41	0.19	0.07	0.08
Operating Expenses
Research & Development	1.32	1.13	1.00	0.88	0.79	0.65	0.66	0.51	0.39
Selling, General & Administrative	1.21	0.98	0.80	0.77	0.62	0.59	0.48	0.38	0.20
Operating Expenses	2.54	2.10	1.80	1.65	1.41	1.24	1.13	0.89	0.59
Operating Income	0.50	-0.18	-0.28	-0.79	-0.71	-0.83	-0.94	-0.81	-0.50
Other Income/Expense
Interest Income	0.11	0.12	0.10	0.02	0.00	0.01	0.03	0.03	0.01
Interest Expense	0.25	0.14	0.12	0.16	0.14	0.08	0.00	0.00	0.00
Other Income/Expense	-0.18	-0.18	-0.13	-0.21	-0.14	-0.03	0.05	0.05	0.01
Income
Income Before Tax	0.32	-0.38	-0.43	-1.13	-0.85	-0.86	-0.89	-0.76	-0.49
Income Tax Expense	0.01	-0.10	0.01	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	0.31	-0.28	-0.44	-1.13	-0.85	-0.86	-0.89	-0.76	-0.49
Net Income - Continuous Operations	0.31	-0.28	-0.44	-1.13	-0.85	-0.86	-0.89	-0.76	-0.49
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	0.56	-0.18	-0.26	-0.93	-0.66	-0.74	-0.87	-0.75	-0.49
EBIT	0.50	-0.24	-0.31	-0.97	-0.71	0.00	0.00	0.00	0.00
Depreciation & Amortization	0.06	0.06	0.05	0.04	0.05	0.03	0.02	0.01	0.01
Earnings Per Share
Basic EPS	2.00	-2.00	-4.00	-9.00	-7.00	-7.00	-8.00	-8.00	-5.00
Diluted EPS	2.00	-2.00	-4.00	-9.00	-7.00	-7.00	-8.00	-8.00	-5.00
Basic Shares Outstanding	0.13	0.13	0.12	0.12	0.12	0.11	0.11	0.10	0.09
Diluted Shares Outstanding	0.13	0.13	0.12	0.12	0.12	0.11	0.11	0.10	0.09